MARKET

CRVS

CRVS

Corvus Pharmaceu
NASDAQ
2.180
-0.060
-2.68%
After Hours: 2.302 +0.122 +5.57% 19:30 03/01 EST
OPEN
2.250
PREV CLOSE
2.240
HIGH
2.280
LOW
2.150
VOLUME
347.27K
TURNOVER
0
52 WEEK HIGH
4.190
52 WEEK LOW
0.6070
MARKET CAP
106.90M
P/E (TTM)
-3.4094
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CRVS last week (0219-0223)?
Weekly Report · 5d ago
Weekly Report: what happened at CRVS last week (0212-0216)?
Weekly Report · 02/19 11:17
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At Keystone Symposia On Systemic Autoimmune and Autoinflammatory Diseases
Corvus' next-generation ITK inhibitor preclinical product candidates are designed to deliver precise T-cell modulation that is optimized for specific immunology indications. The product candidates exhibit specific biologic properties to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
Benzinga · 02/12 13:31
Weekly Report: what happened at CRVS last week (0205-0209)?
Weekly Report · 02/12 11:07
Health Care Sector Update for 02/09/2024: OKYO, HUMA, CRVS
NASDAQ · 02/09 18:54
Health Care Sector Update for 02/09/2024: EMBC, CRVS, ATR, XLV, IBB
NASDAQ · 02/09 14:21
12 Health Care Stocks Moving In Friday's Pre-Market Session
NanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. TC BioPharm (Holdings) stock rose 21.81% and Ontrak (OTRK) stock increased by 11.76%. Corvus Pharma (CRVS) shares also moved upwards during the session.
Benzinga · 02/09 13:06
ABUS, PI and CAMP are among after hour movers
Seeking Alpha · 02/08 22:13
More
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of immune modulator product candidates with the potential to treat solid cancers, T cell lymphomas, autoimmune, allergic and infectious diseases. Its lead product candidate is CPI-818, a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T cell lymphomas. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. Its third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Its product candidate also includes CPI-182, an Anti-CXCR2 Antibody designed to block inflammation and myeloid suppression.

Webull offers Corvus Pharmaceuticals Inc stock information, including NASDAQ: CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.